Genitourinary Cancer

The patient's daughter had not been at the initial consult and thus had only secondhand information from her father and mother.

For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.

Women Against Prostate Cancer provide tips to encourage men to be healthier and signs of prostate cancer to be aware of

The study, published in BJU International, has found that androgen deprivation therapy (ADT) was associated with a 3.3-times increased risk of heart-related deaths in men with congestive heart failure or prior heart attacks.

The Prostate Cancer Foundation (PCF) announced that the partnership with the Movember Foundation has resulted in 7 new Challenge Awards for 2014. In May, it was announced that PCF received over $8.4 million from the Movember Foundation, the leading global organization committed to changing the face of men's health.

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

The Prostate Cancer Foundation (PCF) has awarded 27 new Young Investigator Award selected from 16 countries to advance new drug discovery, immunotherapy, nutritional sciences, and diagnostics for precision medicine.

New research on the risk-reducing benefits of aspirin shed more light on its mechanism of action as well as its potential benefit to reduce the risk of aggressive prostate cancer

Dr. Drew Pinsky's personal battle with prostate cancer inspires him to join forces with PCF

With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option

A new study from Thomas Jefferson University suggests that observation may not be right for all patients with early stage prostate cancer.

The FDA has expanded the approval for the androgen receptor inhibitor enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive mCRPC.

New research suggests that men who aren't well educated about their prostate cancer have a much more difficult time making treatment decisions.

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival

An expert panel and focus groups in Michigan created Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae in 2009 and published an update in July 2014.

Genetics may be to blame for an increase in the number of young men diagnosed with prostate cancer, researchers say.

Rick Bulifant shares his bladder cancer story

It happens all the time. A man gets older, but he doesn't think he needs to be checked for prostate cancer. Even if his father or grandfather had prostate cancer, he feels fine, and does not see the need for yearly physical exams. However, the reality is that 1 in 7 American men will be diagnosed with prostate cancer at some point in his lifetime.

Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists and oncology practitioners in collaboration with primary care physicians.

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research.

Vanna Dest, MSN, APRN-BC, AOCN, Oncology Nurse Practitioner/Manager, Oncology APP, Smilow Cancer Hospital, discusses the risk factors of prostate cancer.

The American Cancer Society has released new Prostate Cancer Survivorship Care guidelines that outline post treatment clinical follow-up care for the myriad of long-term and late effects.

Despite evidence supporting its efficacy, chemotherapy is not routinely administered to patients with muscle-invasive bladder cancer (MIBC)

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC), does not raise the risk for severe toxicities, nor does it affect overall survival (OS)